Health Care Select Sector SPDR® ETF

Changing demographics impact investors in many ways. The demand for bonds could increase, putting downward pressure on yields.

The medical care ratio of health insurance companies is calculated as the ratio of the total money spent in health care claims to premiums earned.

The combined Teva–Allergan generics entity should have approximately 320 Abbreviated New Drug Applications (or ANDAs), including 110 first-to-file ANDAs (or FTF) in the US.

Johnson & Johnson’s (JNJ) Pharmaceuticals segment grew by 1.0% at constant exchange rates, reporting a revenue of $7,946 million for 2Q15 over 2Q14.

In the Rite Aid–Walgreens merger, Walgreens is paying about 0.6x trailing-12-month revenues and 13.6x trailing-12-month EBITDA.

For 2016, Merck & Co. (MRK) reported revenue close to $39.8 billion, a year-over-year (or YoY) rise of ~1%. New product launches have played major roles in boosting Merck’s 2016 revenue.

During the fourth quarter of 2014, Eminence Capital lowered its stake in Humana (HUM). The company accounted for 1.33% of the fund’s 4Q14 portfolio.

the U.S. Food and Drug Administration accepted the filing of a supplemental Biologics License Application for Bristol-Myers Squibb’s Opdivo.

Increased life expectancy means a longer investment horizon. With life expectancy increasing, young investors should invest in equities aggressively.

Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 1Q17, ~$0.46 billion came from its Diabetes segment, representing ~6% of the company total.

Industrials, utilities, and telecommunications have much higher leverage, as these sectors have massive capital needs.

In 2016, Merck’s (MRK) Emend reported revenues of around $549 million, which reflected 3% year-over-year growth.

Sales for Bristol-Myers Squibb’s (BMY) neuroscience segment declined over 80% in 2Q15, while the immunoscience segment’s sales improved ~15% in 2Q15 as compared to 2Q14.

On September 21, 2016, the FDA approved Jannsen Pharmaceuticals’ Invokamet XR for the treatment of adults suffering from Type 2 diabetes.

A major reason for the Pharmacyclics–AbbVie merger is to diversify AbbVie away from its reliance on a single product, Humira, and boost its pipeline.

The hospital sector is widely considered a non-cyclical or defensive industry, meaning demand for hospital services doesn’t change with the economic cycle.

According to estimates by Evaluate Pharma, a whopping $120 billion in sales was lost to patent expirations between 2009 and 2014.

On June 21, Anthem (ANTM) filed a bear hug letter for Cigna (CI). A bear hug letter is a formal press release in which an acquiring company discloses its interest in a target company.

The CPI and PCE are both important indicators of U.S. inflation. CPI is more important from an individual perspective, while PCE is more important for monetary policy.

The health care sector played an important role in the recent bull market (SPX-INDEX) rally.

In terms of payer mix, the percentage of HCA Holdings revenues contributed by Medicare rose from 28.0% in 3Q13 to 30.3% in 3Q14.

As of January 2015, Johnson & Johnson’s ownership structure is dominated by passive investments. They account for more than 80% of the total ownership structure.

The Bureau of Labor Statistics (or BLS) developed the U.S. CPI in 1913 to measure the change in prices.

The U.S. Bureau of Economic Analysis issues PCE data, and the price index is a measure of the average increase in prices for all domestic personal consumption.

On October 18, CNBC reported Bill Gross top picks. His top stock picks were Annaly Capital (NLY), Invesco (IVZ) and Allergan (AGN).

What is a Sharpe ratio? A Sharpe ratio is a tool that measures the amount of returns for each unit of volatility that’s generated by a portfolio (higher returns and lower volatility equals more returns per unit of volatility). The measurement allows investors to analyze how much return they’re receiving from a portfolio in exchange for […]

The 12-month consensus analyst recommendation for Abbott Laboratories on January 18 is a “buy.”

Abiomed’s (ABMD) revenues rose 36% YoY to ~$180 million in fiscal Q1 2019 compared to $133 million in Q1 2018.

January’s JOLTS (Job Openings and Labor Turnover Survey) data, which contains information about job openings and total separations, was reported on March 16.

Johnson & Johnson’s (JNJ) Medical Devices segment includes products for specialty surgery, orthopedics, cardiovascular care, surgical care, diabetes care, and vision care.

According to the December CPI report released by the U.S. Bureau of Labor Statistics on January 12, consumer prices in December increased 0.1%.

In 1Q17, 2Q17, and 3Q17, Amgen’s (AMGN) Enbrel generated revenues of ~$1.2 billion, ~$1.5 billion, and ~$1.4 billion, respectively.

In September 2017, AbbVie’s (ABBV) investigational immunology drug, Upadacitinib (ABT-494), managed to demonstrate its clinical potential.

Lorlatinib is Pfizer’s (PFE) investigational next-generation ALK/ROS-1 tyrosine kinase inhibitor in clinical trials to evaluate its safety and efficacy in the treatment of ALK-positive metastatic non-small cell lung cancer.

The Fed is expected to increase the target funds rate by 0.25% at its December meeting.

Intuitive Surgical’s (ISRG) Da Vinci X received early FDA approval in May 2017 and was given a CE Mark in Europe in April 2017.

In September 2017, AbbVie (ABBV) presented the results from a phase 2B trial of upadacitinib (ABT-494) for the treatment of adult individuals with moderate to severe atopic dermatitis.

According to World Health Organization (or WHO), around 235 million individuals worldwide have asthma.

In June 2017 and July 2017, healthcare providers wrote prescriptions for Regeneron (REGN) and Sanofi’s (SNY) Dupixent for 750 new patients on a weekly basis.

In January 2015, Medtronic (MDT) acquired Covidien for ~$43 billion in cash and MDT stock in a tax inversion deal.

Becton Dickinson’s (BDX) emerging markets registered a strong double-digit growth of 10.9% in 3Q17.

Ramsay Health Care is a market leader in private healthcare in Australia, treating almost 3 million patients each year.

In 2Q17, Celgene’s (CELG) Revlimid generated revenues of ~$2.0 billion, which reflected ~20% growth year-over-year and ~8% growth quarter-over-quarter.

Pfizer (PFE) is extensively conducting clinical trials for the label expansion of Ibrance.

In 2016, Bayer owned ~51,000 valid patent applications and patents relating to ~5,000 protected inventions worldwide.

On June 29, 2017, Thermo Fisher Scientific (TMO) announced the addition of three new products to its semiconductor failure analysis workflows portfolio.

The US medical device industry is a global leader. Its market was valued at ~$140 billion for 2016. It represents ~45% of the global market.

The US economy is dealing with rising healthcare costs. The national healthcare expenditure grew 5.8% to $3.2 trillion in 2015 or $9,990 per person.

The health care sector (IBB) (VHT) (XBI) has been the most challenged sector since Donald Trump’s presidential campaign.

The US GDP growth outlook is near its potential at ~3%, with increased investment in infrastructure.